Beam Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Beam Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BEAM
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201.
CEOJohn Evans
CEOJohn Evans
Employees483
Employees483
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2017
Founded2017
Employees483
Employees483
BEAM Key Statistics
Market cap2.24B
Market cap2.24B
Price-Earnings ratio-4.97
Price-Earnings ratio-4.97
Dividend yield—
Dividend yield—
Average volume2.41M
Average volume2.41M
High today$22.72
High today$22.72
Low today$20.80
Low today$20.80
Open price$21.23
Open price$21.23
Volume2.03M
Volume2.03M
52 Week high$35.25
52 Week high$35.25
52 Week low$13.53
52 Week low$13.53
Stock Snapshot
As of today, Beam Therapeutics(BEAM) shares are valued at $22.03. The company's market cap stands at 2.24B, with a P/E ratio of -4.97.
During the trading session on 2025-11-18, Beam Therapeutics(BEAM) shares reached a daily high of $22.72 and a low of $20.80. At a current price of $22.03, the stock is +5.9% higher than the low and still -3.0% under the high.
Trading volume for Beam Therapeutics(BEAM) stock has reached 2.03M, versus its average volume of 2.41M.
The stock's 52-week range extends from a low of $13.53 to a high of $35.25.
The stock's 52-week range extends from a low of $13.53 to a high of $35.25.
Analyst ratings
88%
of 16 ratingsBuy
87.5%
Hold
12.5%
Sell
0%
People also own
Based on the portfolios of people who own BEAM. This list is generated using Robinhood data, and it’s not a recommendation.